Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S. label ...
Cytokinetics aims to compete with a Bristol Myers Squibb heart drug projected to become a blockbuster seller, and the company’s value proposition is that its drug candidate has a potential safety edge ...
FDA lowers echo monitoring to every 6 months for select Camzyos patients in maintenance phase. Camzyos label update removes prior contraindications with certain CYP inhibitors. See the trading ...
Bristol Myers Squibb BMY suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten). The phase III study was evaluating Camzyos for the treatment of ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration has approved a new ...
Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) turned out to be a conclusive failure, ...
Cytokinetics has set out to prove that aficamten is a threat to Bristol Myers Squibb’s $13.1 billion heart disease drug Camzyos, and a new analysis gives the first shot at an apples-to-apples ...
Cytokinetics, Incorporated remains a Buy following FDA approval of MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM). MYQORZO‘s label offers subtle practical advantages over ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback